KBC Group
SGMO

KBC Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

KBC Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,300
Closed -$102K – 1330
2021
Q3 		$102K Sell
11,300
-11,300
-50% -$112K ﹤0.01% 1163
2021
Q2 		$270K Buy
22,600
+18,000
+391% +$204K ﹤0.01% 1135
2021
Q1 		$58K Hold
4,600
– – ﹤0.01% 1269
2020
Q4 		$395K Hold
4,600
– – ﹤0.01% 1225
2020
Q3 		$44K Hold
4,600
– – ﹤0.01% 1211
2020
Q2 		$42K Buy
4,600
+2,300
+100% +$21.3K ﹤0.01% 1250
2020
Q1 		$15K Hold
2,300
– – ﹤0.01% 1263
2019
Q4 		$19K Buy
2,300
+2,130
+1,253% +$19.6K ﹤0.01% 1456
2019
Q3 		$2K Sell
170
-1,130
-87% -$12.7K ﹤0.01% 1471
2019
Q2 		$14K Hold
1,300
– – ﹤0.01% 1429
2019
Q1 		$12K Buy
1,300
+450
+53% +$4.6K ﹤0.01% 1390
2018
Q4 		$10K Hold
850
– – ﹤0.01% 1293
2018
Q3 		$14K Hold
850
– – ﹤0.01% 1376
2018
Q2 		$12K Buy
850
+400
+89% +$6.64K ﹤0.01% 1276
2018
Q1 		$9K Hold
450
– – ﹤0.01% 1266
2017
Q4 		$7K Buy
+450
New +$6.7K ﹤0.01% 1252

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KBC Group's SGMO Position: Q4 2021 in Review

KBC Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2021, closing a stake of 11,300 shares — an estimated $102K sold.

KBC Group first reported a position in SGMO in Q4 2017 and held it in 16 quarters. The position peaked at $395K in Q4 2020. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2021.

  • KBC Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2021 after selling out during the quarter.
  • KBC Group sold 11,300 SANGAMO THERAPEUTICS INC shares in Q4 2021, an estimated $102K.
  • KBC Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 16 quarters.
  • KBC Group's SANGAMO THERAPEUTICS INC position peaked at $395K in Q4 2020.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2021.

Based on KBC Group's 13F filing for Q4 2021, filed 3 Feb 2022.